Jim Allison

Director of The Parker Institute for Cancer Research, Regental Professor and Chair of the Department of Immunology

Immunology, Immunotherapy

EDUCATION

BS/PhD – The University of Texas, Austin

Postdoctoral Fellow – Molecular Immunology, Scripps Clinic and Research Foundation

AWARDS AND ACCOLADES

Nobel Prize in Physiology or Medicine (2018)

Paul Janssen Award for Biomedical Research (2018)

Wolf Prize for Medicine (2017)

Lasker-DeBakey Clinical Medical Research Award (2015)

Canada Gairdner International Award (2014)

Breakthrough Prize in Life Sciences (2014)

COMPANIES AND BOARDS

Co-Founder –  Jounce Therapeutics, Neon

Scientific Advisory Board – Achelios, Affini-T, Apricity, Asher Bio, Bio Alta, LLC, Candel Therapeutics, Carisma, Codiak Biosciences, C-Reveal Therapeutics, Dragonfly Therapeutics, Earli Inc, Enable Medicine, Glympse Bio, Henlius/Hengenix, Hummingbird, ImaginAB, Infinity Pharma, InterVenn Biosciences, Lava Therapeutics, Lytix BioPharma, Marker Therapeutics, Oncolytics, PBM Capital, Phenomic AI, Polaris Pharma, Trained Therapeutix Discovery, Two Bear Capital, Xilis, Inc.

MEMBER OF Investment Committee

Associated Portfolio Companies

No items found.